These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 1826187)
1. Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group. Lehtonen A Am Heart J; 1991 Apr; 121(4 Pt 2):1307-11. PubMed ID: 1826187 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients. Talseth T; Westlie L; Daae L; Vatle S Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752 [TBL] [Abstract][Full Text] [Related]
3. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861 [TBL] [Abstract][Full Text] [Related]
4. Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison. Lijnen P; Fagard R; Staessen J; Amery A Methods Find Exp Clin Pharmacol; 1990 Oct; 12(8):563-73. PubMed ID: 2151197 [TBL] [Abstract][Full Text] [Related]
5. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension. Torvik D; Madsbu HP Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855 [TBL] [Abstract][Full Text] [Related]
6. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Torvik D; Madsbu HP Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):69S-75S. PubMed ID: 2939870 [TBL] [Abstract][Full Text] [Related]
7. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension. Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854 [TBL] [Abstract][Full Text] [Related]
8. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins. Lehtonen A; Himanen P; Saraste M; Niittymäki K; Marniemi J Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):77S-81S. PubMed ID: 2939871 [TBL] [Abstract][Full Text] [Related]
9. Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. Lijnen P; Fagard R; Staessen J; Lissens W; Amery A J Cardiovasc Pharmacol; 1989 Aug; 14(2):319-25. PubMed ID: 2476608 [TBL] [Abstract][Full Text] [Related]
10. Clinical experience with doxazosin in general medical practice. Rosenthal J Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745 [TBL] [Abstract][Full Text] [Related]
11. Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency. Bartels AC; de Vries PM; Oe LP; van Bronswÿk H; Donker AJ; Réveillaud RJ; Fillastre JP; Zech P Am Heart J; 1988 Dec; 116(6 Pt 2):1772-7. PubMed ID: 2904749 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension. Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914 [TBL] [Abstract][Full Text] [Related]
14. Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. Mazzola C; Guerrasio E Am Heart J; 1988 Dec; 116(6 Pt 2):1797-801. PubMed ID: 2904753 [TBL] [Abstract][Full Text] [Related]
15. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. Frick MH; Halttunen P; Himanen P; Huttunen M; Pörsti P; Pitkäjärvi T; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):55S-62S. PubMed ID: 2939868 [TBL] [Abstract][Full Text] [Related]
16. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol. Baez MA; Garg DC; Jallad NS; Weidler DJ Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):63S-67S. PubMed ID: 2939869 [TBL] [Abstract][Full Text] [Related]
17. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Pool JL Am Heart J; 1991 Jan; 121(1 Pt 2):251-9; discussion 259-60. PubMed ID: 1824647 [TBL] [Abstract][Full Text] [Related]
18. Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report. Langdon CG Am Heart J; 1991 Jan; 121(1 Pt 2):268-73. PubMed ID: 1824649 [TBL] [Abstract][Full Text] [Related]
19. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus. Castrignano R; D'Angelo A; Pati T; Al Awady M; Tronca R; Crepaldi G Am Heart J; 1988 Dec; 116(6 Pt 2):1778-84. PubMed ID: 2904750 [TBL] [Abstract][Full Text] [Related]
20. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. Rosenthal J Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]